Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol

Journal of Virological Methods

Volumn 194, Issue 1-2, 2013, Pages 300-307

  Bronze, M ^a,b   Aitken, S C ^c   Wallis, C L ^a   Steegen, K ^a   Stuyver, L J ^d   de Wit, T F Rinke ^e   Stevens, W ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antiretroviral drug resistance; Genotyping; HIV 1 virological failure assay

Indexed keywords

ANTIRETROVIRUS AGENT;

ACCURACY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; COST; DIAGNOSTIC KIT; DRIED BLOOD SPOT TESTING; DRUG TREATMENT FAILURE; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VIROLOGICAL FAILURE ASSAY; VIRUS EXAMINATION; VIRUS LOAD;

ANTIRETROVIRAL DRUG RESISTANCE; GENOTYPING; HIV-1 VIROLOGICAL FAILURE ASSAY;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 84885216650     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.08.015     Document Type: Article

References (26)

1. Aitken S., Bronze M., Wallis C., Stuyver L., Steegen K., Balinda S., Kityo C., Stevens W., Rinke de Wit T.F., Schuurman R. A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. Journal of Clinical Microbiology 2013, 51:1757-1761.
2. Aitken S., Kliphuis A., Bronze M., Wallis C., Kityo C., Balinda S., Stevens W., Spieker N., de Oliveira T., Rinke de Wit T.F., Schuurman R. Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots. Journal of Clinical Microbiology 2013, 51(June):1899-1905.
3. Balinda S., Ondoa P., Kliphuis A., Egau I., Bronze M., Kasambula L., Obuku E., Schuurman R., Spieker N., Rinke de Wit T.F., Kityo C. Evaluation of a viral failure assay using Dried Blood spots in three clinical settings in Uganda. African Society of Laboratory Medicine International Conference 2012.
4. Barth R., Loeff Mfs., Schuurman R., Hoepelman A., Wensing A. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa? A systematic review. Lancet Infectious Diseases 2010, 10:155-166. 10.1016/S1473-3099(09)70328-7.
5. Bland J., Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 8:307-310.
6. Brambilla D., Granger S., Bremer J. Variation in HIV RNA assays at low RNA concentration. 7th Conf. Retrovir. Opportunist. Infect (p. Abstract 774) 2000.
7. Brehm J., Koontz D., Wallis C., Shutt K., Sanne I., Wood R., McIntyre J., Stevens W.S., Sluis-Cremer N., Mellors J.W. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with faialure of inital therapy reduces susceptibility to reverse-transcriptase inhibitors\. Clinical Infectious Diseases 2012, 55:737-745.
8. Conradie F., Wilson D., Basson A., De Oliveira T., Hunt G., Joel D., Papathanasopoulos M., Preiser W., Klausner J., Spencer D., Stevens W., Venter F., van Vuuren C., Levin L., Meintjes G., Orrell C., Sunpath H., Rossouw T., van Zyl G. Guidelines: the 2012 southern African ARV drug resistance testing guidelines. Southern African Journal of HIV Medicine 2012, 13:162-167.
9. ® v1.5 using specimens from East Africa. Journal of virological methods 2009, 162(1-2):218-222.
10. El-Khatib Z., Ekstrom A., Ledwaba J., Mohapi L., Laher F., Karstaedt A., Charalambous S., Petzold M., Katzenstein D., Morris L. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010, 24(July):1679-1687.
11. Hamers R., Oyomopito R., Kityo C., Phanuphak P., Siwale M., Sungkanuparph S., Conradie F., Kumarasamy N., Botes M.E., Sirisanthana T., Abdallah S., Li P.C., Ngorima N., Kantipong P., Osibogun A., Lee C.K., Stevens W.S., Kamarulzaman A., Derdelinckx I., Chen Y.M., Schuurman R., Vugt M.V., Rinke de Wit T.F., on behalf of the P.A.(PASER) and T.A.(TASER) S.to E.R. Cohort Profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. International Journal of Epidemiology 2011, (Epub ahead of print).
12. Martin D., Gottesman B., Grossman Z., Lorber M., Levi I., Shitrit P., Katzir M., Gottesman G., Chowers M. Comparative performance of the Amplicor HIV-1 Monitor assay versus NucliSens EasyQ in HIV subtype C-infected patients. Journal of Medical Virology 2006, 78:883-887.
13. Masciotra S., Garrido C., Youngpairoj A., McNulty A., Zahonero N., Corral A., Heneine W., de Mendoza C., García-Lerma J.G. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007, 21(November):2503-2511.
14. Monleau M., Butel C., Delaport E., Boillot F., Peeters M. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. Journal of Antimicrobial Chemotherapy 2010, 65:1562-1566.
15. National Department of Health Clinical Guidelines for the Management of HIV & AIDS in Adults and Adolescents 2010, National Department of Health, South Africa, Retrieved from: http://www.fidssa.co.za/Guidelines/2010_Adult_ART_Guidelines.pdf (accessed 28.01.13).
16. Rhee S.-J., Gonzales M., Kantor R., Betts B., Ravela J., Shafer R. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2003, 31:298-303.
17. Scott L., Carmona S., Stevens W. Performance of the New Roche Cobas AmpliPrep-Cobas TaqMan Version 2.0 human immunodeficiency virus type 1 assay. Journal of Clinical Microbiology 2009, 47:3400-3402.
18. Scott L.E., Galpin J.S., Glencross D.K. Multiple method comparison? Statistical model using percentage similarity. European Journal of Clinical Chemistry and Clinical Biochemistry 2003, 53(October):46-53. 10.1002/cyto.b.10016.
19. Scott L., Noble L., Moloi J., Erasmus L., Venter W., Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS Easy. Journal of Clinical Microbiology 2009, 47:2209-2217.
20. Struck D., Wallis C., Denisov G., Lambert C., Servais J., Viana R., Letsoalo E., Bronze M., Aitken S.C., Schuurman R., Stevens W., Schmit J.C., Rinke de Wit T., Perez Bercoff D. Automated sequence analysis and editing software for HIV drug resistance testing. Journal of Clinical Virology 2012, 54(May):30-35.
21. Van Zyl G., Van Mens T., McIlleron H., Zeier M., Nachega J., Decloedt E., Malavazzi C., Smith P., Huang Y., van der Merwe L., Gandhi M., Maartens G. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes 2011, 56(April):333-339.
22. Wallis C.L., Mellors J.W., Venter W.D.F., Sanne I., Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-Containing antiretroviral therapy in South Africa. AIDS Research and Treatment 2011, 769627. 10.1155/2011/769627.
23. Wallis C.L., Papathanasopoulos M.A., Lakhi S., Karita E., Kaleebu P., Sanders E., Anzala O., Bekker L.G., Stevens G., de Wit T.F., Stevens W. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. Journal of Virological Methods 2010, 163:505-508. 10.1016/j.jviromet.2009.11.011.
24. WHO Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2010 Revision 2010, World Health Organization, Geneva, Retrieved December 19, 2012, from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (accessed 01.07.11).
25. WHO The Strategic Use of Antiretrovirals to Help in the HIV Epidemic 2012, Retrieved from: http://apps.wo.int/iris/blitstream/10665/75184/1/9789241503921_eng.pdf (accessed 19.12.12).
26. WHO/UNAIDS/UNICEF Progress Report 2011: Global HIV/AIDS Response 2011, Retrieved from: http://www.who.int/hiv/pub/progress_report2011/en/index.html (accessed 19.12.12).